{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:38:31Z","timestamp":1780555111230,"version":"3.54.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key R&D Program of China","doi-asserted-by":"crossref","award":["2022YFC2504402"],"award-info":[{"award-number":["2022YFC2504402"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Emergency Key Program of Guangzhou Laboratory","award":["EKPG21-17"],"award-info":[{"award-number":["EKPG21-17"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270081"],"award-info":[{"award-number":["82270081"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"crossref","award":["2020A1515011459"],"award-info":[{"award-number":["2020A1515011459"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"DOI":"10.1186\/s12985-025-02964-8","type":"journal-article","created":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T09:03:25Z","timestamp":1762247005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials"],"prefix":"10.1186","volume":"22","author":[{"given":"Yongbo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoyong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiantao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihai","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaixiang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jincun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Sang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2964_CR1","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1056\/NEJMc2214314","volume":"388","author":"J Miller","year":"2023","unstructured":"Miller J, Hachmann NP, Collier AY, Lasrado N, Mazurek CR, Patio RC, Powers O, Surve N, Theiler J, Korber B, Barouch DH. Substantial neutralization escape by SARS-CoV-2 Omicron variants BQ.1.1 and XBB.1. N Engl J Med. 2023;388:662\u20134.","journal-title":"N Engl J Med"},{"key":"2964_CR2","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41579-022-00809-7","volume":"21","author":"M Cox","year":"2023","unstructured":"Cox M, Peacock TP, Harvey WT, Hughes J, Wright DW, Consortium C-GU, Willett BJ, Thomson E, Gupta RK, Peacock SJ, Robertson DL, Carabelli AM. SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. Nat Rev Microbiol. 2023;21:112\u201324.","journal-title":"Nat Rev Microbiol"},{"key":"2964_CR3","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1056\/NEJMc2202879","volume":"386","author":"PE Brown","year":"2022","unstructured":"Brown PE, Fu SH, Bansal A, Newcombe L, Colwill K, Mailhot G, Delgado-Brand M, Gingras AC, Slutsky AS, Pasic M, Companion J, Bogoch II, Morawski E, Lam T, Reid A, Jha P, Ab CSC, Ab CSI. Omicron BA.1\/1.1 SARS-CoV-2 infection among vaccinated Canadian adults. N Engl J Med. 2022;386:2337\u20139.","journal-title":"N Engl J Med"},{"key":"2964_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/d41586-023-00014-3","volume":"613","author":"E Callaway","year":"2023","unstructured":"Callaway E. Coronavirus variant XBB.1.5 rises in the united States - is it a global threat? Nature. 2023;613:222\u20133.","journal-title":"Nature"},{"key":"2964_CR5","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1016\/j.cell.2022.09.018","volume":"185","author":"I Kimura","year":"2022","unstructured":"Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, Kobiyama K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, Ishii KJ, Japan C, Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 2022;185:3992\u2013e400716.","journal-title":"Cell"},{"key":"2964_CR6","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.22.525079","author":"N Lasrado","year":"2023","unstructured":"Lasrado N, Collier AY, Miller J, Hachmann NP, Liu J, Sciacca M, et al. Waning immunity against XBB.1.5 following bivalent mRNA boosters. bioRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.01.22.525079.","journal-title":"bioRxiv"},{"key":"2964_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1056\/NEJMc2215471","volume":"388","author":"DY Lin","year":"2023","unstructured":"Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, Sunny SK, Moore Z. Effectiveness of bivalent boosters against severe Omicron infection. N Engl J Med. 2023;388:764\u20136.","journal-title":"N Engl J Med"},{"key":"2964_CR8","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1056\/NEJMc2214916","volume":"388","author":"J Zou","year":"2023","unstructured":"Zou J, Kurhade C, Patel S, Kitchin N, Tompkins K, Cutler M, Cooper D, Yang Q, Cai H, Muik A, Zhang Y, Lee DY, Sahin U, Anderson AS, Gruber WC, Xie X, Swanson KA, Shi PY. Neutralization of BA.4-BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with bivalent vaccine. N Engl J Med. 2023;388:854\u20137.","journal-title":"N Engl J Med"},{"issue":"4","key":"2964_CR9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI154987","volume":"132","author":"J Zou","year":"2022","unstructured":"Zou J, Li L, Zheng P, Liang W, Hu S, Zhou S, et al. Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance. J Clin Invest. 2022;132(4):e154987. https:\/\/doi.org\/10.1172\/JCI154987.","journal-title":"J Clin Invest"},{"key":"2964_CR10","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo CG, Tse LV, Kaku CI, Wrapp D, Sakharkar M, Huang D, Deveau LM, Yockachonis TJ, Herbert AS, Battles MB, O\u2019Brien CM, Brown ME, Geoghegan JC, Belk J, Peng L, Yang L, Hou Y, Scobey TD, Burton DR, Nemazee D, Dye JM, Voss JE, Gunn BM, McLellan JS, Baric RS, Gralinski LE, Walker LM. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science. 2021;371:823\u20139.","journal-title":"Science"},{"key":"2964_CR11","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, Jaconi S, Culap K, Zatta F, De Marco A, Peter A, Guarino B, Spreafico R, Cameroni E, Case JB, Chen RE, Havenar-Daughton C, Snell G, Telenti A, Virgin HW, Lanzavecchia A, Diamond MS, Fink K, Veesler D, Corti D. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature. 2020;583:290\u20135.","journal-title":"Nature"},{"key":"2964_CR12","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.chom.2021.12.010","volume":"30","author":"K Vanshylla","year":"2022","unstructured":"Vanshylla K, Fan C, Wunsch M, Poopalasingam N, Meijers M, Kreer C, Kleipass F, Ruchnewitz D, Ercanoglu MS, Gruell H, Munn F, Pohl K, Janicki H, Nolden T, Bartl S, Stein SC, Augustin M, Dewald F, Gieselmann L, Schommers P, Schulz TF, Sander LE, Koch M, Luksza M, Lassig M, Bjorkman PJ, Klein F. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell Host Microbe. 2022;30:69\u2013e8210.","journal-title":"Cell Host Microbe"},{"key":"2964_CR13","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.chom.2022.07.002","volume":"30","author":"H Gruell","year":"2022","unstructured":"Gruell H, Vanshylla K, Korenkov M, Tober-Lau P, Zehner M, Munn F, Janicki H, Augustin M, Schommers P, Sander LE, Kurth F, Kreer C, Klein F. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns. Cell Host Microbe. 2022;30:1231\u201341. e6.","journal-title":"Cell Host Microbe"},{"key":"2964_CR14","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41467-020-20501-9","volume":"12","author":"J Ge","year":"2021","unstructured":"Ge J, Wang R, Ju B, Zhang Q, Sun J, Chen P, Zhang S, Tian Y, Shan S, Cheng L, Zhou B, Song S, Zhao J, Wang H, Shi X, Ding Q, Liu L, Zhao J, Zhang Z, Wang X, Zhang L. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry. Nat Commun. 2021;12:250.","journal-title":"Nat Commun"},{"key":"2964_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.abm8143","volume":"375","author":"YJ Park","year":"2022","unstructured":"Park YJ, De Marco A, Starr TN, Liu Z, Pinto D, Walls AC, et al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science. 2022;375:449\u201354.","journal-title":"Science"},{"key":"2964_CR16","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-021-03696-9","volume":"595","author":"Z Wang","year":"2021","unstructured":"Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, Hoffmann HH, Barnes CO, Cipolla M, Ramos V, Oliveira TY, Cho A, Schmidt F, Da Silva J, Bednarski E, Aguado L, Yee J, Daga M, Turroja M, Millard KG, Jankovic M, Gazumyan A, Zhao Z, Rice CM, Bieniasz PD, Caskey M, Hatziioannou T, Nussenzweig MC. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021;595:426\u201331.","journal-title":"Nature"},{"key":"2964_CR17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1093\/protein\/gzq002","volume":"23","author":"L Benatuil","year":"2010","unstructured":"Benatuil L, Perez JM, Belk J, Hsieh CM. An improved yeast transformation method for the generation of very large human antibody libraries. Protein Eng Des Sel. 2010;23:155\u20139.","journal-title":"Protein Eng Des Sel"},{"key":"2964_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/978-1-61779-921-1_5","volume":"899","author":"Q Zhao","year":"2012","unstructured":"Zhao Q, Zhu Z, Dimitrov DS. Yeast display of engineered antibody domains. Methods Mol Biol. 2012;899:73\u201384.","journal-title":"Methods Mol Biol"},{"key":"2964_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41421-022-00509-9","volume":"9","author":"Y Wang","year":"2023","unstructured":"Wang Y, Yan A, Song D, Dong C, Rao M, Gao Y, Qi R, Ma X, Wang Q, Xu H, Liu H, Han J, Duan M, Liu S, Yu X, Zong M, Feng J, Jiao J, Zhang H, Li M, Yu B, Wang Y, Meng F, Ni X, Li Y, Shen Z, Sun B, Shao X, Zhao H, Zhao Y, Li R, Zhang Y, Du G, Lu J, You C, Jiang H, Zhang L, Wang L, Dou C, Liu Z, Zhao J. Biparatopic antibody BA7208\/7125 effectively neutralizes SARS-CoV-2 variants including Omicron BA.1-BA.5. Cell Discov. 2023;9:3.","journal-title":"Cell Discov"},{"key":"2964_CR20","doi-asserted-by":"publisher","first-page":"819058","DOI":"10.3389\/fimmu.2022.819058","volume":"13","author":"Y Du","year":"2022","unstructured":"Du Y, Zhang S, Zhang Z, Miah KM, Wei P, Zhang L, et al. Intranasal lentiviral vector-mediated antibody delivery confers reduction of SARS-CoV-2 infection in elderly and immunocompromised mice. Front Immunol. 2022;13:819058.","journal-title":"Front Immunol"},{"key":"2964_CR21","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1172\/JCI138759","volume":"130","author":"Y Wang","year":"2020","unstructured":"Wang Y, Zhang L, Sang L, Ye F, Ruan S, Zhong B, Song T, Alshukairi AN, Chen R, Zhang Z, Gan M, Zhu A, Huang Y, Luo L, Mok CKP, Al Gethamy MM, Tan H, Li Z, Huang X, Li F, Sun J, Zhang Y, Wen L, Li Y, Chen Z, Zhuang Z, Zhuo J, Chen C, Kuang L, Wang J, Lv H, Jiang Y, Li M, Lin Y, Deng Y, Tang L, Liang J, Huang J, Perlman S, Zhong N, Zhao J, Malik Peiris JS, Li Y, Zhao J. Kinetics of viral load and antibody response in relation to COVID-19 severity. J Clin Invest. 2020;130:5235\u201344.","journal-title":"J Clin Invest"},{"key":"2964_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100893","volume":"4","author":"I Ullah","year":"2023","unstructured":"Ullah I, Beaudoin-Bussieres G, Symmes K, Cloutier M, Ducas E, Tauzin A, et al. The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice. Cell Rep Med. 2023;4:100893.","journal-title":"Cell Rep Med"},{"key":"2964_CR23","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-555612\/v1","author":"R Yamin","year":"2021","unstructured":"Yamin R, Jones AT, Hoffmann HH, Kao KS, Francis RL, Sheahan TP, Baric RS, Rice CM, Ravetch JV, Bournazos S. Fc-engineered antibody therapeutics with improved efficacy against COVID-19. Res Sq. 2021. https:\/\/doi.org\/10.21203\/rs.3.rs-555612\/v1.","journal-title":"Res Sq"},{"key":"2964_CR24","doi-asserted-by":"publisher","first-page":"e0267796","DOI":"10.1371\/journal.pone.0267796","volume":"17","author":"RV House","year":"2022","unstructured":"House RV, Broge TA, Suscovich TJ, Snow DM, Tomic MT, Nonet G, et al. Evaluation of strategies to modify anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics. PLoS ONE. 2022;17:e0267796.","journal-title":"PLoS ONE"},{"key":"2964_CR25","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, Luo Y, Chu H, Huang Y, Nair MS, Yu J, Chik KK, Yuen TT, Yoon C, To KK, Chen H, Yin MT, Sobieszczyk ME, Huang Y, Wang HH, Sheng Z, Yuen KY, Ho DD. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022;602:676\u201381.","journal-title":"Nature"},{"key":"2964_CR26","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","volume":"602","author":"Y Cao","year":"2022","unstructured":"Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, Huang W, Li Q, Wang P, An R, Wang J, Wang Y, Niu X, Yang S, Liang H, Sun H, Li T, Yu Y, Cui Q, Liu S, Yang X, Du S, Zhang Z, Hao X, Shao F, Jin R, Wang X, Xiao J, Wang Y, Xie XS. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602:657\u201363.","journal-title":"Nature"},{"key":"2964_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1056\/NEJMc2214302","volume":"388","author":"M Imai","year":"2023","unstructured":"Imai M, Ito M, Kiso M, Yamayoshi S, Uraki R, Fukushi S, Watanabe S, Suzuki T, Maeda K, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Halfmann PJ, Kawaoka Y. Efficacy of antiviral agents against Omicron subvariants BQ.1.1 and XBB. N Engl J Med. 2023;388:89\u201391.","journal-title":"N Engl J Med"},{"key":"2964_CR28","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1038\/s41467-023-38345-4","volume":"14","author":"CI Kaku","year":"2023","unstructured":"Kaku CI, Starr TN, Zhou P, Dugan HL, Khalif\u00e9 P, Song G, Champney ER, Mielcarz DW, Geoghegan JC, Burton DR, Andrabi R, Bloom JD, Walker LM. Evolution of antibody immunity following Omicron BA.1 breakthrough infection. Nat Commun. 2023;14:2751.","journal-title":"Nat Commun"},{"key":"2964_CR29","doi-asserted-by":"publisher","first-page":"e0266250","DOI":"10.1371\/journal.pone.0266250","volume":"17","author":"T Sulea","year":"2022","unstructured":"Sulea T, Baardsnes J, Stuible M, Rohani N, Tran A, Parat M, Cepero Donates Y, Duchesne M, Plante P, Kour G, Durocher Y. Structure-based dual affinity optimization of a SARS-CoV-1\/2 cross-reactive single-domain antibody. PLoS ONE. 2022;17:e0266250.","journal-title":"PLoS ONE"},{"key":"2964_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101577","volume":"5","author":"DJ Sheward","year":"2024","unstructured":"Sheward DJ, Pushparaj P, Das H, Greaney AJ, Kim C, Kim S, et al. Structural basis of broad SARS-CoV-2 cross-neutralization by affinity-matured public antibodies. Cell Rep Med. 2024;5:101577.","journal-title":"Cell Rep Med"},{"key":"2964_CR31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-022-00401-6","volume":"8","author":"Y Wang","year":"2022","unstructured":"Wang Y, Liu M, Shen Y, Ma Y, Li X, Zhang Y, et al. Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses. Cell Discov. 2022;8:36.","journal-title":"Cell Discov"},{"key":"2964_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41421-022-00497-w","volume":"8","author":"H Ma","year":"2022","unstructured":"Ma H, Zhang X, Zeng W, Zhou J, Chi X, Chen S, et al. A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration. Cell Discov. 2022;8:132.","journal-title":"Cell Discov"},{"key":"2964_CR33","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-021-03461-y","volume":"593","author":"R De Gasparo","year":"2021","unstructured":"De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593:424\u20138.","journal-title":"Nature"},{"key":"2964_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33030-4","volume":"13","author":"MR Chang","year":"2022","unstructured":"Chang MR, Tomasovic L, Kuzmina NA, Ronk AJ, Byrne PO, Johnson R, et al. IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern. Nat Commun. 2022;13:5814.","journal-title":"Nat Commun"},{"key":"2964_CR35","doi-asserted-by":"publisher","first-page":"109363","DOI":"10.1016\/j.isci.2024.109363","volume":"27","author":"T Inoue","year":"2024","unstructured":"Inoue T, Yamamoto Y, Sato K, Okemoto-Nakamura Y, Shimizu Y, Ogawa M, Onodera T, Takahashi Y, Wakita T, Kaneko MK, Fukasawa M, Kato Y, Noguchi K. Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies. iScience. 2024;27:109363.","journal-title":"iScience"},{"key":"2964_CR36","doi-asserted-by":"publisher","first-page":"1155293","DOI":"10.3389\/fcimb.2023.1155293","volume":"13","author":"K Yu","year":"2023","unstructured":"Yu K, Liu B, Yu H, Sun C, Wang X, Li G, Dong M, Wang Y, Zhang J, Xu N, Liu W. A neutralizing bispecific single-chain antibody against SARS-CoV-2 Omicron variant produced based on CR3022. Front Cell Infect Microbiol. 2023;13:1155293.","journal-title":"Front Cell Infect Microbiol"},{"key":"2964_CR37","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-021-03461-y","volume":"593","author":"R De Gasparo","year":"2021","unstructured":"De Gasparo R, Pedotti M, Simonelli L, Nickl P, Muecksch F, Cassaniti I, Percivalle E, Lorenzi JCC, Mazzola F, Magr\u00ec D, Michalcikova T, Haviernik J, Honig V, Mrazkova B, Polakova N, Fortova A, Tureckova J, Iatsiuk V, Di Girolamo S, Palus M, Zudova D, Bednar P, Bukova I, Bianchini F, Mehn D, Nencka R, Strakova P, Pavlis O, Rozman J, Gioria S, Sammartino JC, Giardina F, Gaiarsa S, Pan-Hammarstr\u00f6m Q, Barnes CO, Bjorkman PJ, Calzolai L, Piralla A, Baldanti F, Nussenzweig MC, Bieniasz PD, Hatziioannou T, Prochazka J, Sedlacek R, Robbiani DF, Ruzek D, Varani L. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature. 2021;593:424\u20138.","journal-title":"Nature"},{"issue":"8","key":"2964_CR38","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/vaccines11081320","volume":"11","author":"HJ Hyun","year":"2023","unstructured":"Hyun HJ, Choi MJ, Nham E, Seong H, Yoon JG, Noh JY, et al. Neutralizing activity against BQ.1.1, BN.1, and XBB.1 in bivalent COVID-19 vaccine recipients: comparison by the types of prior infection and vaccine formulations. Vaccines (Basel). 2023;11(8):1320. https:\/\/doi.org\/10.3390\/vaccines11081320.","journal-title":"Vaccines (Basel)"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12985-025-02964-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-025-02964-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:03:26Z","timestamp":1762290206000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-025-02964-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2964"],"URL":"https:\/\/doi.org\/10.1186\/s12985-025-02964-8","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,4]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors affiliated with Innovent Biologics are employees of Innovent Biologics (Suzhou), who is commencing the commercialization of IBI314. The other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"358"}}